Stuut A, Nijssen C, van der Wagen L, van Rhenen A, Daenen L, Janssen A
Bone Marrow Transplant. 2025; .
PMID: 40089614
DOI: 10.1038/s41409-025-02538-w.
Bar M, El Anbari M, Rinchai D, Toufiq M, Kizhakayil D, Manjunath H
Cancers (Basel). 2025; 17(5).
PMID: 40075650
PMC: 11899482.
DOI: 10.3390/cancers17050802.
Karumathil S, Kulkarni U, Selvarajan S, Lionel S, Devasia A, Aboobacker F
Blood Cell Ther. 2025; 8(1):147-159.
PMID: 40061177
PMC: 11883483.
DOI: 10.31547/bct-2024-002.
Masuda Y, Honda A, Oyama T, Masamoto Y, Kurokawa M
Int J Hematol. 2025; .
PMID: 40032737
DOI: 10.1007/s12185-025-03949-7.
Feng J, Zhang X, Tan Z, Zhao Y, Hu H, Chen J
Front Med (Lausanne). 2025; 11:1523909.
PMID: 39944817
PMC: 11815662.
DOI: 10.3389/fmed.2024.1523909.
Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience.
Uchibori Y, Kurosawa S, Najima Y, Haraguchi K, Sadato D, Hirama C
Front Immunol. 2025; 16:1521895.
PMID: 39944683
PMC: 11814185.
DOI: 10.3389/fimmu.2025.1521895.
Rapid tapering of cyclosporine after allogeneic transplantation for high-risk hematological malignancies.
Gomyo A, Kako S, Kawamura M, Kawamura S, Takeshita J, Yoshino N
Int J Hematol. 2025; .
PMID: 39912986
DOI: 10.1007/s12185-024-03913-x.
HLA-matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML.
Mitsuyoshi T, Arai Y, Kondo T, Kawata T, Hirabayashi S, Tanaka M
EJHaem. 2025; 6(1):e21088.
PMID: 39866933
PMC: 11756973.
DOI: 10.1002/jha2.1088.
Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients.
Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F
Cancers (Basel). 2025; 17(2).
PMID: 39858092
PMC: 11763395.
DOI: 10.3390/cancers17020310.
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group.
Giordano U, Piekarska A, Prejzner W, Gil L, Zaucha J, Kujawska J
Biomedicines. 2025; 13(1).
PMID: 39857747
PMC: 11759780.
DOI: 10.3390/biomedicines13010163.
Hereditary non-spherocytic hemolytic anemia with GPI mutations successfully treated with allogeneic hematopoietic stem cell transplantation: a first report of two cases.
Li H, Wang J, Rong L, Li J, Xue Y, Fang Y
J Mol Med (Berl). 2025; 103(3):265-271.
PMID: 39836218
DOI: 10.1007/s00109-025-02514-3.
The antibiotic de-escalation strategy in patients with multidrug-resistant bacterial colonization after allogeneic stem cell transplantation.
Bono R, Sapienza G, Tringali S, Rotolo C, Santoro A, Di Noto L
Front Microbiol. 2025; 15():1487617.
PMID: 39831122
PMC: 11739814.
DOI: 10.3389/fmicb.2024.1487617.
Incidence, risk factors, and outcomes of transplant-associated thrombotic microangiopathy in pediatric patients after allogeneic hematopoietic cell transplantation: a single-institution prospective study.
Yoon S, Kang S, Kim H, Choi E, Im H, Koh K
Bone Marrow Transplant. 2025; .
PMID: 39815034
DOI: 10.1038/s41409-024-02506-w.
Bronchial structural changes analyzed with three-dimensional computed tomography correlate with severe acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation.
Fujioka Y, Nakamura Y, Yamamoto K, Tokunaga Y, Nono S, Sasaki T
Ann Hematol. 2025; 104(1):729-740.
PMID: 39805943
PMC: 11868157.
DOI: 10.1007/s00277-025-06195-3.
The role of fat-soluble vitamins for graft-versus host disease after myeloablative conditioning in allogeneic stem cell transplanted patients.
Skaarud K, Gudmundstuen A, Pesonen M, Hjermstad M, Iversen P, Tjonnfjord G
Sci Rep. 2025; 15(1):1675.
PMID: 39799129
PMC: 11724905.
DOI: 10.1038/s41598-024-84805-2.
Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann J, Seidl C
Front Immunol. 2024; 15:1413927.
PMID: 39737173
PMC: 11683009.
DOI: 10.3389/fimmu.2024.1413927.
Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study.
Hu Z, Feng Z, Liu S, He H, Dong Y, Fan Z
BMC Med. 2024; 22(1):605.
PMID: 39736728
PMC: 11687046.
DOI: 10.1186/s12916-024-03830-0.
[Clinical characteristics of cytokine release syndrome after haploidentical hematopoietic stem cell transplantation for thalassemia major].
Zhou X, Wang X, Lin Q, Wang C, Yang C, Li Y
Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(12):1301-1307.
PMID: 39725393
PMC: 11684831.
DOI: 10.7499/j.issn.1008-8830.2406036.
Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.
Zhang A, Huang Z, Zhang R, Wei R, Jiang S, Chen H
Br J Haematol. 2024; 206(2):615-627.
PMID: 39710371
PMC: 11829143.
DOI: 10.1111/bjh.19958.
A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia.
Yang H, Li X, Que L, Chen H, Zhan L, Zhou D
Stem Cell Res Ther. 2024; 15(1):495.
PMID: 39709479
PMC: 11663346.
DOI: 10.1186/s13287-024-04103-6.